Novartis invests in early technical development capabilities for next-generation biotherapeutics
- Details
- Category: Novartis

FDA grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus vaccine candidate
- Details
- Category: Pfizer

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
- Details
- Category: Sanofi

BioNTech's statement on patent infringement lawsuit filed by Moderna
- Details
- Category: Business

Moderna sues Pfizer and BioNTech for infringing patents central to Modernas innovative mRNA technology platform
- Details
- Category: Business

Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
- Details
- Category: Novartis

The spin-off aims to maximize shareholder value by creating the #1 European generics company(1) and a global leader in biosimilars, allowing Novartis shareholders to participate fully in the potential future upside for both Sandoz and Novartis Innovative Medicines.
Pfizer and BioNTech submit application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine
- Details
- Category: Pfizer

More Pharma News ...
- Bayer supports demining in Ukraine with donation to non-profit "Fondation suisse de déminage"
- Pfizer announces positive top-line results from Phase 3 study of 20-valent pneumococcal conjugate vaccine in infants
- Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
- Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
- Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
- Bayer Consumer Health leaders propose new principles for science-led self-care
- GSK signs agreement to support pandemic preparedness in Europe